MedTrace Logo

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

NCT05805072 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of selinexor and HAAG +/- HMA in relapsed/refractory acute leukemia (AML) patients.

Conditions

  • Relapsed/Refractory AML

Interventions

DRUG

Selinexor

Selinexor 60 mg/day, orally on d1,4,8,11

DRUG

Homoharringtonine

Homoharringtonine 1 mg/day intravenously on days 3 to 9

DRUG

Cytarabine

cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9

DRUG

Aclacinomycin

aclacinomycin 10 mg/day intravenously on days 3 to 6

DRUG

Granulocyte Colony-Stimulating Factor

granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,

DRUG

Decitabine

Decitabine 20 mg/m2/day intravenously on days 1 to 5.

DRUG

Azacitidine

Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05805072 on ClinicalTrials.gov